Literature DB >> 10221364

The serotonin syndrome and its treatment.

P K Gillman1.   

Abstract

Serotonin syndrome is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine. The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various subtypes of serotonin receptors. There is no effective drug treatment established. The history of the treatment of serotonin syndrome with 5-hydroxytryptamine blocking drugs is reviewed. A literature search was undertaken using both Medline and a manual search of the older literature. Reports of cases treated with the 5-HT2 blockers cyproheptadine and chlorpromazine were identified and analysed. There is some evidence suggesting the efficacy of chlorpromazine and cyproheptadine in the treatment of serotonin syndrome. The evidence for cyproheptadine is less substantial, perhaps because the dose of cyproheptadine necessary to ensure blockade of brain 5-HT2 receptors is 20-30 mg, which is higher than that used in the cases reported to date (4-16 mg).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221364     DOI: 10.1177/026988119901300111

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  30 in total

Review 1.  Serotonin syndrome: a brief review.

Authors:  Philippe Birmes; Dominique Coppin; Laurent Schmitt; Dominique Lauque
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

2.  Clomipramine and neuroleptic malignant syndrome: literature on adverse reactions to psychotropic drugs continues to confuse.

Authors:  Geoffrey K Isbister; Nicholas A Buckley
Journal:  BMJ       Date:  2005-04-02

3.  [The serotonin syndrome. Fatal course of intoxication with citalopram and moclobemide].

Authors:  S Cassens; E A Nickel; M Quintel; P Neumann
Journal:  Anaesthesist       Date:  2006-11       Impact factor: 1.041

4.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

5.  Recognition and treatment of serotonin syndrome.

Authors:  Christopher Frank
Journal:  Can Fam Physician       Date:  2008-07       Impact factor: 3.275

6.  Linezolid and serotonin syndrome.

Authors:  Davin K Quinn; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

Review 7.  Controversies in Serotonin Syndrome Diagnosis and Management: A Review.

Authors:  Mohd Faisal Uddin; Richard Alweis; Syed Raza Shah; Noman Lateef; Waqas Shahnawaz; Rohan Kumar Ochani; Amin Muhammad Dharani; Syed Arbab Shah
Journal:  J Clin Diagn Res       Date:  2017-09-01

8.  Management of hot flashes in women with breast cancer.

Authors:  L Kligman; J Younus
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

9.  An interesting case of serotonin syndrome precipitated by escitalopram.

Authors:  Debasish Sanyal; Suddhendu Chakraborty; Ranjan Bhattacharyya
Journal:  Indian J Pharmacol       Date:  2010-12       Impact factor: 1.200

Review 10.  A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.

Authors:  Fabrizio Schifano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.